40 Percent of Commercially Insured Individuals Affected by Copay Accumulator and Maximizer Programs in 2025

As of late 2025, approximately 40% of commercially insured individuals were enrolled in health plans utilizing copay accumulator or maximizer programs, according to recent data. These benefit designs redirect manufacturers’ copay assistance away from patients and toward insurers and pharmacy benefit managers (PBMs). Patients who depend on single-source, brand-name specialty medications for conditions such as autoimmune diseases, multiple sclerosis, and cancer are increasingly encountering these programs. The widespread adoption of these tools highlights their growing impact across the healthcare landscape.

The report indicates that copay accumulators and maximizers have gained traction due to the financial advantages they offer plan sponsors. These programs generate savings for payers while boosting profits for PBMs. However, patients often find themselves navigating a complex system marked by multiple tiers, deductibles, coinsurance requirements, exclusions, and other intricate benefit structures. Despite efforts by some states to limit the use of these tools through legislative measures, their reach remains restricted. The findings underscore the ongoing challenges posed by these programs within an already complicated drug distribution system.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 10, 2026

Author

GOAI